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Advances in Knowledge and Implications for patient care: We hereby report novel glutamine-based PETtracers. These tracers are tagged on the arene group with fluorine-18, hereby preventing in vivo defluorination, which can occur with alkyl labelled tracers (e.g. (2S,4R)4-[
18 F]fluoroglutamine). [
Introduction
The introduction of nuclear medicine in clinical practice has shifted the use of imaging in oncology. While magnetic resonance imaging (MRI) and computed tomography (CT) visualize tumor anatomy, the addition of nuclear medicine provides a more functional understanding. Positron emission tomography (PET) is a nuclear medicine technique for biomedical imaging that uses radiotracers interacting with some of the hallmarks in cancer, making it possible to visualize what is happening on a molecular level [1] [2] [3] [2] [3] [4] . Nevertheless, [
18 F]FDG is of limited value for tumors with high background uptake (e.g. brain tumors), low tumor uptake (e.g. neuroendocrine tumors, prostate cancer, hepatocellular carcinoma) or in the presence of tumor-associated inflammation [5] [6] [7] [8] .
Amino acids also show increased uptake in malignant cells and seem to overcome several of the glucose- [5] [6] [7] [8] . Another amino acid that draws attention in cancer metabolism is glutamine 9 .
Being the most abundant amino acid in blood and muscle, glutamine is also an essential amino acid for malignant cells as several tumors seem to be unable to survive without the presence of exogenous glutamine. It is both a carbon and nitrogen source and participates in the cellular redox homeostasis, which explains the "glutamine addiction" [10] [11] [12] [13] . Some tumors have even been reported to metabolically shift to glutaminolysis, resulting in negative [ 18 F]FDG PET scans 14, 15 . All these aspects led to the development of glutamine-based PET tracers e.g. [17] [18] [19] [20] .
In this study, we further elaborated on the glutamine-derived PET-tracers. Therefore, we aimed to obtain fluorine-18 labelled inhibitors of the alanine-serine-cysteine transporter-2 (ASCT-2), the most important glutamine transporter. The first radiotracer we synthesized was the fluorine-18 variant of the known inhibitor L-γ-glutamyl-p-nitroanilide (GPNA) 21 . For the second radiotracer we decided to expand the aromatic system of GPNA to a biphenyl group. As such, we aimed at a better affinity for the ASCT-2 transporter by better filling the hydrophilic pocket described in different homology models [21] [22] [23] . The organic synthesis of both precursors and cold reference products was based on a method described by Schulte et al. 22 . In order to avoid interference with the glutamine backbone, implementation of the radioisotope was performed directly at the aromatic rings. Therefore, we attempted to develop the fluorine-18 labeled derivative of glutamine via a ruthenium-based direct aromatic fluorination method. Both tracers were evaluated in vitro for their affinity towards the glutamine transporters. Finally, as a proof of concept, PETimages were acquired in a mouse model for prostate cancer and a rat model for glioblastoma.
Materials & methods a. General
All reactions described were performed under nitrogen atmosphere. 
b. Chemistry
General procedure A (amine acylation of aniline with protected glutamate)
To a heat-dried flask containing the Boc-L-Glu-OtBu (500 mg, 1.65 mmol, 1.00 eq), aniline (1.65 mmol,
hexafluorophosphate (HATU) (627 mg, 1.65 mmol, 1.00 eq), diisopropylethylamine (DIPEA) (0.57 mL, 3.30 mmol, 2.00 eq) and a magnetic stirring bar under N2 gas was added anhydrous DMF (18 mL, 11mL/ mmol) as a solvent. The reaction mixture was stirred overnight at 120 °C. The next day the solution was cooled to room temperature and DMF was evaporated in vacuo. Next, the mixture was partitioned in water/ CH2Cl2, and extracted with CH2Cl2 (2x). The organic layer was dried by passing it over a Büchner funnel filled with sodium sulphate. The filtrate was absorbed onto celite®, concentrated in vacuo and purified by flash chromatography on silica gel (hexane:ethyl acetate).
General procedure B (cleavage of tert-butyl and N-boc protection groups)
The purified compounds were dissolved in 4.0M HCl in dioxane (10 mL/ mmol) in an anhydrous environment and were stirred 4 hours at 40 °C. The reaction mixture was concentrated in vacuo and used without further purification.
Boc-L-Glu-OtBu (500 mg, 1.65 mmol) and 4-fluoroaniline (183 mg, 1.65 mmol) were coupled using procedure A. The mixture, absorbed onto celite®, was purified using automated flash chromatography 
tert-Butyl N2-(tert-butoxycarbonyl)-N5-(4-hydroxyphenyl)glutaminate (2)
Boc-L-Glu-OtBu (500 mg, 1.65 mmol) and 4-aminophenol (180 mg, 1.65 mmol) were coupled using procedure A. The mixture, absorbed onto celite®, was purified using automated flash chromatography 
tert-Butyl N2-(tert-butoxycarbonyl)-N5-(4'-hydroxy-[1,1'-biphenyl]-4-yl)glutaminate (4)
Boc-L-Glu-OtBu (500 mg, 1.65 mmol) and 4'-amino-[1,1'-biphenyl]-4-ol (305 mg, 1.65 mmol) were coupled using procedure A. The mixture, absorbed onto celite®, was purified using automated flash chromatography (20→ 50% EtOAc in hexane) to afford 4 (442 mg, 0.94 mmol) as a white powder in 57%
yield. Rf 0.37 (50% EtOAc/ 50% Hex 
N5-(4-fluorophenyl)glutamine (5)
The tert-butyl and N-boc protection groups of compound 1 were removed using procedure B, to obtain compound 5, a white powder, in quantitative yields. 
N5-(4'-fluoro-[1,1'-biphenyl]-4-yl)glutamine (6)
The tert-butyl and N-boc protection groups of compound 3 were removed using procedure B, to obtain compound 6, a white powder, with quantitative yields. 1 
F]FBPG)
The chemical labelling of compounds 2 and 4 with fluorine-18 was done via an aromatic fluorination method described by Beyzavi et al. 24 . The fluoride used for these reactions was produced in a cyclone 18/9 cyclotron (IBA) with a 18 O(p,n) nuclear reaction. The [ and heating the vial for 3.5 minutes to 90°C. After cooling down the mixture, mobile phase (300 µL) was added to neutralize the pH. Purification was then done by injecting onto HPLC using a C18 prep column (Atlantis T3 OBD prep column, 100 Å, 10 µM, 10mm x 250mm, 1/pkg, Waters). Elution of the desired radiotracer was followed with a radiodetector (Ludlum Measurements Inc) coupled to the HPLC. and was diluted with PBS before further usage.
Quality control of the obtained radiotracer was done by means of analytical HPLC with radio-and UV detection (205 nm; Waters) using a 1.0 mL/min flow and a Grace Alltima C18 (4.6x250 mm; 5 µm) column.
The retention times of the fluorine-18 labelled compounds were compared to the retention time of the vortexed and centrifuged (10 min; 1100 g) where after aliquots were taken from each layer which were measured in a NaI (Tl) scintillation counter (Capintec; Ramsey, NJ, USA). LogD7.4 was calculated as the logarithm of the proportion of counts in the octanol and PBS layers.
d. In vitro experiments

General information
The PC-3 and F98 cell lines were purchased from ATCC and the SLC1A5 knock-out cell line from Creative
Biogene. The PC-3 cell line was cultivated in RPMI medium enriched with 10% fetal calf serum, 1% Lglutamine and penicillin/streptomycin (50 U/mL). Both the F98 cell line and SLC1A5 knock-out cell line were cultivated in Dulbecco's modified Eagle's medium (DMEM) enriched with 10% fetal calf serum, 1%
L-glutamine and penicillin/streptomycin (50 U/mL). All cell lines were stored in an incubator set to 37 °C and 5% CO2 environment. The presence of ASCT-2 expression in PC-3 and F98 cell lines was verified with flow cytometry. The analysis was performed using the LSR II (BD Biosciences) as described by De Munter et al. 35 . Both cell lines (100,000 cells/ 100 µL) were stained at their surface with a primary (rabbit ab;
ASCT-2 (V501)) and secondary antibody (Fab2 (PE Conjugate); anti-rabbit IgG) against ASCT-2 as a negative control. The cells were fixed and permeabilized followed by intracellular binding with the primary antibody. After binding of the primary antibody, the secondary antibody was added and after the incubation period, all samples were analyzed. The ASCT-2 knock-out cell line was engineered with CRISPR-CAS 9 using a HEK293 cell line. Absence of ASCT-2 was also explored via flow cytometry. The percentage of ASCT-2 positive cells was < 1%, indicating that the knock-out efficiency approximates 100%.
Cell tests were performed in 24-well plates (VWR, US). PC-3, F98 and SLC1A5 KO cells were seeded the day prior to the test in a concentration of respectively 175,000; 125,000 and 175,000 cells per milliliter.
The 24-well plates used for the cell tests with the knock-out cell line were coated prior to seeding to achieve good attachment of the cells. To coat the plate 300 µL of Poly-D-lysine stock solution (0.1 mg/mL) was added to each well. The plates were dried for 30 minutes until all solvent was removed. 
In vitro evaluation of stability in formulation
e. In vivo experiments
All animal experiments were in accordance with the regulations set up by the Ghent University Ethical
Committee and were approved prior to the start of the study by the local Ethical Committee on Animal Experiments (ECD 17/08 and ECD 18/21). During housing water and food was provided ad libitum.
Animals were fasted minimal six hours prior to PET scans. Anesthesia was induced with 5.0% isoflurane (V:V in O2) and maintained with 2.0% until the end of the experiment. After intravenous injection in the lateral tail vein, 1-hour dynamic PET acquisitions were performed on a FLEX Triumph II small animal PET/CT-scanner (PET field of view: 7.5 cm axial; 1.3 mm spatial resolution; TriFoil Imaging). Upon completion of the PET-scan an additional CT-scan was performed for anatomical correlation purposes. 
SUV = (Radioactivity in ROI/ injected activity) x body weight
with injected activity corrected for radioactive decay and residual radioactivity in the syringe.
PC-3 xenograft model
At the day of inoculation, the PC-3 cells were harvested and suspended in non-enriched RPMI medium to obtain a 5 x 10 7 cells/ mL cell suspension. Male swiss nu/nu mice (n=5) were inoculated with 5 x 10 6 PC- 
Orthotopic F98 model
The F98 glioblastoma rat model was obtained by the same method described by Verhoeven et al. 36 . A suspension of 20 x 10 3 F98 tumor cells was injected into the right frontal lobe of female Fischer rats (n=3).
Tumor growth was visualized using T2-weighted and contrast-enhanced T1-weighted MRI (7T PharmaScan 70/16, Bruker BioSpin, Ettlingen, Germany). Upon tumor confirmation on MRI (± 12 days post inoculation), dynamic PET acquisitions were obtained after injection of 37 MBq radiotracer. Coregistration of the images was done in PMOD. First, the CT-MRI and CT-PET images were aligned. Next the MRI images were aligned to the PET images. Tumor tissue was delineated based on the contrastenhancing region on T1-weighted MRI. A reference region (2 x 2 x 2 mm 3 ) was delineated contralateral to the tumor.
Results
a. Chemistry
The synthetic approach for both the precursors and cold reference products of [ 18 
c. In vitro experiments
Flow cytometry
Flow cytometry confirmed the expression of ASCT-2 on both the PC-3 and F98 cell line (see Figure 1) .
The PC-3 cell line showed a median population of 12,056 while the median population of the negative control was 576. In comparison, the median population in the F98 was 28,585 with a median population of the negative control of 919. 
Concentration dependency
Affinity constants Ki were calculated for both compounds and can be found in Table 1 1 . FPG shows moderate affinity towards the ASCT-2 transporter on the human PC-3 cell line and a low affinity to the transporter expressed on the rat F98 cell line. FBPG has low affinity to the transporter on both PC-3 and 
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in the absence of the ASCT-2 transporter. As such, they inhibit the other glutamine transporting proteins, indicating that they are not specific for ASCT-2.
In vitro stability
Both [ 
d. In vivo experiments
PC-3 xenograft model
Semi-quantitative values for both radiotracers can be found in Table 3 3 .
[ 18 F]FPG shows moderate tumor uptake in the mice bearing PC-3 xenografts (see Figure 3) . Only a very low uptake in the PC-3 xenograft was seen for [ 18 F]FBPG (see Figure 3 ). 
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Semi-quantitative analysis
The acquired PET data of 
Discussion
The metabolic importance of glutamine in tumor biology raised the overall interest for amino acid derivatives as molecular probes. Research has led to the development of both therapeutic and diagnostic compounds targeting their transporters and metabolic enzymes [25] [26] [27] [28] . Due to the drawbacks of [ 18 F]FDG and the "glutamine addiction" of several tumors, different PET radiotracers based on the glutamine backbone have been developed [5] [6] [7] [8] [10] [11] [12] [13] 16, 17 . In this study, we developed and characterized [ 21 . Exploring a range of substitutions on the aromatic ring could provide more insight into the exact configuration of the lipophilic pocket described by several authors [21] [22] [23] . In this work, we developed a biphenyl analogue to exploit the lipophilic pocket and thereby increasing the affinity. However, the introduction of the second aromatic ring had a detrimental effect on the binding towards the ASCT-2 transporter. Therefore, we believe that the lipophilic pocket is limited in size and by introducing a second
Conclusion
We investigated the imaging potential of two novel PET radiotracers [ 
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